These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33432682)

  • 41. Cytokine-release hypersensitivity reaction after the first dose of benralizumab for severe eosinophilic asthma.
    Morgenstern-Kaplan D; Vasquez-Echeverri E; Carrillo-Martin I; Chiarella SE; Gonzalez-Estrada A
    Ann Allergy Asthma Immunol; 2021 Dec; 127(6):701-702. PubMed ID: 34391900
    [No Abstract]   [Full Text] [Related]  

  • 42. Benralizumab for Prednisone-Dependent Eosinophilic Asthma Associated With Novel STAT3 Loss of Function Mutation.
    Adatia A; Allen CJ; Wald J; Richards CD; Waserman S; Nair P
    Chest; 2021 Apr; 159(4):e181-e184. PubMed ID: 34022014
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mepolizumab (Nucala) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jan; 58(1486):11-2. PubMed ID: 26761344
    [No Abstract]   [Full Text] [Related]  

  • 44. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
    Dávila González I; Moreno Benítez F; Quirce S
    J Investig Allergol Clin Immunol; 2019 Apr; 29(2):84-93. PubMed ID: 31017107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
    Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
    Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recurrence of eosinophilic inflammation and worsening asthma symptoms between doses of benralizumab.
    Cormier M; Cartier A
    J Allergy Clin Immunol Pract; 2020; 8(10):3605-3607. PubMed ID: 32603903
    [No Abstract]   [Full Text] [Related]  

  • 47. Mepolizumab for Treatment of Severe Eosinophilic Asthma: A 5-Year Real-World Experience.
    Loli-Ausejo D; Perdomo G; Mascaró B; Martínez-Olondris P; Sánchez-Fernández MC; Mullol J; Valero A; Arismendi E; Bobolea I
    J Investig Allergol Clin Immunol; 2023 Jun; 33(3):209-210. PubMed ID: 36820628
    [No Abstract]   [Full Text] [Related]  

  • 48. Real-world effectiveness of benralizumab in US subspecialist-treated adults with severe asthma: Findings from CHRONICLE.
    Panettieri RA; Lugogo N; Moore WC; Chipps BE; Jepson B; Zhou W; Ambrose CS; Genofre E; Carstens DD
    Respir Med; 2023 Sep; 216():107285. PubMed ID: 37290579
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan.
    Park HS; Kim MK; Imai N; Nakanishi T; Adachi M; Ohta K; Tohda Y;
    Int Arch Allergy Immunol; 2016; 169(3):135-45. PubMed ID: 27097165
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
    Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials.
    Tian BP; Zhang GS; Lou J; Zhou HB; Cui W
    J Asthma; 2018 Sep; 55(9):956-965. PubMed ID: 29211545
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
    Comberiati P; McCormack K; Malka-Rais J; Spahn JD
    J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
    Khorasanizadeh M; Eskian M; Assa'ad AH; Camargo CA; Rezaei N
    Int Rev Immunol; 2016 Jul; 35(4):294-311. PubMed ID: 27119985
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relapsing chronic eosinophilic pneumonia treated successfully with benralizumab.
    Ricketti PA; Ricketti AJ
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):726-727. PubMed ID: 33636343
    [No Abstract]   [Full Text] [Related]  

  • 55. High serum cytokine levels may predict the responsiveness of patients with severe asthma to benralizumab.
    Watanabe S; Suzukawa M; Tashimo H; Ohshima N; Asari I; Imoto S; Kobayashi N; Tohma S; Nagase T; Ohta K
    J Asthma; 2022 Aug; 59(8):1604-1612. PubMed ID: 34121592
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
    Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
    Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
    Hillas G; Fouka E; Papaioannou AI
    Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
    [No Abstract]   [Full Text] [Related]  

  • 58. Biologics for oral corticosteroid-dependent asthma.
    Yılmaz İ
    Allergy Asthma Proc; 2020 May; 41(3):151-157. PubMed ID: 32375958
    [No Abstract]   [Full Text] [Related]  

  • 59. Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis.
    Lugogo N; Liu MC; Pavord I; Mitchell PD; Smith SG; Mallett S; Albers FC; Bradford ES; Yancey SW; Bel EH
    J Allergy Clin Immunol Pract; 2021 Sep; 9(9):3506-3509.e3. PubMed ID: 34111572
    [No Abstract]   [Full Text] [Related]  

  • 60. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials.
    Liu T; Wang F; Wang G; Mao H
    Front Med; 2018 Jun; 12(3):340-349. PubMed ID: 29086236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.